ArticleOncoTargets and therapy2020
Prognostic Value of Ki67 in Patients with Stage 1-2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor.
Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- Prognostic Significance of the Ki-67 Index with an Optimal Cut-off Value of 32.5% in Uterine Sarcoma and Uterine Carcinosarcoma: A Retrospective Cohort Study.International journal of women's health · 2026Article
- Predictive value of IGF2BP2 for endometrial cancer recurrence: a multicenter study.Frontiers in oncology · 2026Article
- Comparative effects of estradiol and daidzein on the expression of endometrial cancer-related genes and histopathological parameters in the uterus of ovariectomized rats.Iranian journal of basic medical sciences · 2026Article
- Article
- Risk Stratification Prediction of Endometrial Cancer Using Microstructural Mapping Based on Time-Dependent Diffusion MRI.Cancer science · 2025Article
- Nomogram Incorporating Inflammatory Index, Pathology, and Molecular Classification for Predicting Recurrence in Patients with Stage I-III Endometrial Cancer: A Multi-Institutional Study.Journal of inflammation research · 2025Article
- Prognostic significance and immune infiltration analysis of HMGA2 in endometrial cancer.Frontiers in immunology · 2025Article
- Simultaneous effect of naringenin and beta-catenin signaling inhibitor C-82 on modulating gene expression and functional pattern of mesenchymal stem cells from endometriosis patients.Iranian journal of basic medical sciences · 2025Article
- Predicting recurrence of non-muscle invasive bladder urothelial carcinoma: predictive value of the optimal cut-off value of Ki67.Frontiers in oncology · 2024Article
- Enhancing Tamoxifen Therapy with α-Mangostin: Synergistic Antiproliferative Effects on Breast Cancer Cells and Potential Reduced Endometrial Impact.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Systemic analysis of the expression and prognostic significance of USP31 in endometrial cancer.Biomolecules & biomedicine · 2023Article
- Article
- Effects of an inhibitor of the SHH signaling pathway on endometrial cells of patients with endometriosis.BMC molecular and cell biology · 2022Article
- The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?Reproductive sciences (Thousand Oaks, Calif.) · 2022Review
- Estrogen Receptor- And Progesterone Receptor-Positive Thresholds in Predicting the Recurrence of Early Low-Risk Endometrial Cancer.Clinical Medicine Insights. Oncology · 2022Article
- A Nomogram Model for Predicting Recurrence of Stage I-III Endometrial Cancer Based on Inflammation-Immunity-Nutrition Score (IINS) and Traditional Classical Predictors.Journal of inflammation research · 2022Article
- The impact of Ki-67 index, squamous differentiation, and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer.Bosnian journal of basic medical sciences · 2021Article
- Analysis of Factors Related to Lymph Node Metastasis in Early-Stage Type 1 Endometrial Cancer: Verifying the Clinical Value of Positive Threshold of the Immunohistochemical Parameter Ki67.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to find a cut-off value of the immunohistochemical parameter Ki67 for stage I-II endometrial cancer. MATERIALS AND
methodsThe clinicopathological data of 318 patients with stages I-II endometrial cancer who received primary surgical treatment were retrospectively analyzed. A cut-off value of Ki67 for predicting recurrence of endometrial cancer was determined by using the receiver operating characteristic curve and the Youden index. The Cox regression was performed to screen factors associated with recurrence of endometrial cancer. Based on the cut-off value of Ki67, the patients were divided into two groups, and the differences of clinicopathological parameters between the two groups were compared.
resultsThe receiver operating characteristic curve showed that the optimal cut-off value of Ki67 for predicting recurrence of patients with stages I-II endometrial cancer was 38%. The multivariate Cox regression analysis demonstrated that the histotypes (
conclusionThe Ki67 was demonstrated to be a useful prognostic factor in patients with stages I-II endometrial cancer, and the Ki67 labeling index 38.0% was optimal cut-off value for predicting recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.